Immunomodulatory function of interleukin 28B during primary infection with cytomegalovirus

Journal of Infectious Diseases

Volumn 210, Issue 5, 2014, Pages 717-727

  Egli, Adrian ^a,b,e   Levin, Aviad ^a   Santer, Deanna M ^a   Joyce, Michael ^a   O'Shea, Daire ^a   Thomas, Brad S ^a   Lisboa, Luiz F ^a   Barakat, Khaled ^a,c   Bhat, Rakesh ^a   Fischer, Karl P ^a   Houghton, Michael ^a   Tyrrell, D Lorne ^a   Kumar, Deepali ^d   Humar, Atul ^d  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF BASEL   (Switzerland)

^c FAYOUM UNIVERSITY   (Egypt)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Adaptive immune response; Cytomegalovirus; Feedback mechanism; Immunosuppression; Innate immune response; Interferon ; Interferon stimulated gene; Interleukin 28; Solid organ transplantation; T cell priming

Indexed keywords

ALPHA2 INTERFERON; BETA INTERFERON; CD14 ANTIGEN; CD40 ANTIGEN; CD45RA ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 28A; INTERLEUKIN 28B; INTERLEUKIN 29; MESSENGER RNA; SMALL INTERFERING RNA; STAT2 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS INFECTION; DOWN REGULATION; EX VIVO STUDY; FEMALE; FIBROBLAST; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC TRANSFECTION; GENOTYPE; GRAFT RECIPIENT; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN FORESKIN FIBROBLAST; IFIT2 GENE; IL 28B GENE; IMMUNOMODULATION; INFECTION RISK; INNATE IMMUNITY; INTRACELLULAR SIGNALING; ISG15 GENE; LYMPHOCYTE PROLIFERATION; MALE; MX1 GENE; NEWBORN; NONHUMAN; OAS1 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIMARY INFECTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOCS1 GENE; SURVIVAL RATE; USP18 GENE; VIRUS REPLICATION;

ADAPTIVE IMMUNE RESPONSE; CYTOMEGALOVIRUS; FEEDBACK MECHANISM; IMMUNOSUPPRESSION; INNATE IMMUNE RESPONSE; INTERFERON Λ; INTERFERON-STIMULATED GENE; INTERLEUKIN 28; SOLID ORGAN TRANSPLANTATION; T-CELL PRIMING;

ADULT; AGED; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FIBROBLASTS; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTERLEUKINS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSPLANTATION; VIRUS REPLICATION;

EID: 84907424313     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu144     Document Type: Article

References (49)

1. Booth D, George J. Loss of function of the new interferon IFN-lambda4 may confer protection from hepatitis C. Nat Genet 2013; 45:119-20.
2. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77.
3. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011; 60:1284-93.
4. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-68.
5. Yin Z, Dai J, Deng J, et al. Type III IFNs Are Produced by and Stimulate Human Plasmacytoid Dendritic Cells. J Immunol 2012; 189:2735-45.
6. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genomewide association study. Gastroenterology 2010; 138:1338-45, 45 e1-7.
7. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-9.
8. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-4.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
10. Bibert S, Roger T, Calandra T, et al. IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med 2013; 210:1109-16.
11. Chinnaswamy S, Chatterjee S, Boopathi R, Mukherjee S, Bhattacharjee SKundu TK. A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-kappaB-mediated gene transcription. PLoS One 2013; 8: e75495.
12. Fischer J, Bohm S, Scholz M, et al. Combined effects of different interleukin- 28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012; 55:1700-10.
13. Smith KR, Suppiah V, O'Connor K, et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a crosssectional European cohort. Genome Med 2011; 3:57.
14. Sugiyama M, Tanaka Y, Wakita T, Nakanishi M, Mizokami M. Genetic variation of the IL-28B promoter affecting gene expression. PLoS One 2011; 6:e26620.
15. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140:1021-31.
16. Shi X, Pan Y, Wang M, et al. IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One 2012; 7:e37054.
17. Abe H, Hayes CN, Ochi H, et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83:1597-607.
18. Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim MH, Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009; 15:31-3.
19. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139:499-509.
20. Maekawa S, Sakamoto M, Miura M, et al. Comprehensive analysis for viral elements and il28b polymorphisms in response to peginterferon plus ribavirin therapy in HCV-1b infection. Hepatology 2012; 56:1611-21.
21. Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4:725-38.
22. Humar A, Snydman D. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S78-86.
23. Egli A, Humar A, Kumar D. State-of-the-art on monitoring of cytomegalovirus- specific cell mediated immunity after organ transplant - a primer for the clinician. Clin Infect Dis 2012; 55:1678-89.
24. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-53.
25. Loewendorf A, Benedict CA. Modulation of host innate and adaptive immune defenses by cytomegalovirus: timing is everything. J Intern Med 2010; 267:483-501.
26. Humar A, Mazzulli T, Moussa G, et al. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5:1065-70.
27. Lisboa LF, Asberg A, Kumar D, et al. The clinical utility of whole blood versus plasma cytomegalovirus viral load assays for monitoring therapeutic response. Transplantation 2011; 91:231-6.
28. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
29. Egli A, Binet I, Binggeli S, et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008; 6:29.
30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29:e45.
31. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009; 284:20869-75.
32. Miknis ZJ, Magracheva E, Li W, Zdanov A, Kotenko SV, Wlodawer A. Crystal structure of human interferon-lambda1 in complex with its high-affinity receptor interferon-lambdaR1. J Mol Biol 2010; 404: 650-64.
33. Fenner JE, Starr R, Cornish AL, et al. Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 2006; 7:33-9.
34. Waiboci LW, Ahmed CM, Mujtaba MG, et al. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS- 1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist. J Immunol 2007; 178: 5058-68.
35. Spadaro F, Lapenta C, Donati S, et al. IFN-alpha enhances crosspresentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood 2012; 119:1407-17.
36. Alderson MR, Armitage RJ, Tough TW, Strockbine L, Fanslow WC, Spriggs MK. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med 1993; 178:669-74.
37. Fecteau JF, Neron S. CD40 stimulation of human peripheral B lymphocytes: distinct response from naive and memory cells. J Immunol 2003; 171:4621-9.
38. Bravo D, Solano C, Gimenez E, et al. Effect of the IL28B Rs12979860 C/T polymorphism on the incidence and features of active cytomegalovirus infection in allogeneic stem cell transplant patients. J Med Virol 2014; 86:838-44.
39. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-44.
40. Feld JJ, Nanda S, Huang Y, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007; 46:1548-63.
41. Lau DT, Negash A, Chen J, et al. Innate immune tolerance and the role of Kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013; 144:402-13.
42. Duarte-Rojo A, Veldt BJ, Goldstein DD, et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation 2012; 27:197-203.
43. Cisneros E, Banos I, Citores MJ, et al. Increased risk of severe hepatitis C virus recurrence after liver transplantation in patients with a T allele of IL28B rs12979860. Transplantation 2012; 94:275-80.
44. Paludan SR, Bowie AG, Horan KA, Fitzgerald KA. Recognition of herpesviruses by the innate immune system. Nat Rev Immunol 2011; 11:143-54.
45. Brand S, Beigel F, Olszak T, et al. IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 2005; 289:G960-8.
46. Francois-Newton V, Magno de Freitas Almeida G, Payelle-Brogard B, et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS One 2011; 6:e22200.
47. Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142:978-88.
48. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887-98.
49. Chi B, Dickensheets HL, Spann KM, et al. Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus. J Virol 2006; 80:5032-40.